Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Brotchie

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Current Opinion in Pharmacology|January 29, 2003
CB1 cannabinoid receptor signalling in Parkinson's diseaseJonathan M Brotchie
Movement Disorders : Official Journal of the Movement Disorder Society|July 12, 2005
Nondopaminergic mechanisms in levodopa-induced dyskinesiaJonathan M Brotchie
Experimental Neurology|August 9, 2011
5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanismsPhilippe Huot, Jonathan M Brotchie
Current Protocols in Pharmacology|September 29, 2011
MPTP-induced models of Parkinson's disease in mice and non-human primatesNaomi P Visanji, Jonathan M Brotchie
The European Journal of Neuroscience|October 1, 2018
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?Susan H Fox, Jonathan M Brotchie
Progress in Brain Research|October 5, 2010
The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and futureSusan H Fox, Jonathan M Brotchie
Current Opinion in Investigational Drugs (London, England : 2000)|August 10, 2004
Drugs in development for Parkinson's diseaseTom H Johnston, Jonathan M Brotchie
Movement Disorders : Official Journal of the Movement Disorder Society|July 12, 2002
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned ratJoanne E Nash, Jonathan M Brotchie
Current Opinion in Investigational Drugs (London, England : 2000)|January 24, 2006
Drugs in development for Parkinson's disease: an updateTom H Johnston, Jonathan M Brotchie
BMC Neurology|June 22, 2011
Pros and cons of a prion-like pathogenesis in Parkinson's diseaseRuediger Hilker, Jonathan M Brotchie, Joab Chapman
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Current Opinion in Pharmacology|January 29, 2003
CB1 cannabinoid receptor signalling in Parkinson's diseaseJonathan M Brotchie
Movement Disorders : Official Journal of the Movement Disorder Society|July 12, 2005
Nondopaminergic mechanisms in levodopa-induced dyskinesiaJonathan M Brotchie
Experimental Neurology|August 9, 2011
5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanismsPhilippe Huot, Jonathan M Brotchie
Current Protocols in Pharmacology|September 29, 2011
MPTP-induced models of Parkinson's disease in mice and non-human primatesNaomi P Visanji, Jonathan M Brotchie
The European Journal of Neuroscience|October 1, 2018
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?Susan H Fox, Jonathan M Brotchie
Progress in Brain Research|October 5, 2010
The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and futureSusan H Fox, Jonathan M Brotchie
Current Opinion in Investigational Drugs (London, England : 2000)|August 10, 2004
Drugs in development for Parkinson's diseaseTom H Johnston, Jonathan M Brotchie
Movement Disorders : Official Journal of the Movement Disorder Society|July 12, 2002
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned ratJoanne E Nash, Jonathan M Brotchie
Current Opinion in Investigational Drugs (London, England : 2000)|January 24, 2006
Drugs in development for Parkinson's disease: an updateTom H Johnston, Jonathan M Brotchie
BMC Neurology|June 22, 2011
Pros and cons of a prion-like pathogenesis in Parkinson's diseaseRuediger Hilker, Jonathan M Brotchie, Joab Chapman
Pageof 13